Fivephusion

University of Wollongong Secures $500K Grant to Advance ResectAssist™ Cancer Device for Pancreatic Tumors

- University of Wollongong researchers received $500,000 from Australian Economic Accelerate Ignite Grants to develop ResectAssist™, a biodegradable implantable device for inoperable pancreatic cancer. - The device delivers high-dose chemotherapy directly into tumors using standard endoscopy techniques, aiming to convert non-resectable pancreatic tumors to resectable ones. - ResectAssist™-FOLFIRINOX delivers the FOLFIRINOX chemotherapy regimen locally to maximize anti-cancer efficacy while minimizing systemic side effects. - The collaboration between UOW and FivepHusion targets pancreatic cancer, which has survival rates under 10% and represents one of the most challenging cancers to treat.